BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33481646)

  • 1. Lipiodol as a Predictive Indicator for Therapy Response to Transarterial Chemoembolization of Hepatocellular Carcinoma.
    Langenbach MC; Vogl TJ; Said G; Scholtz JE; Hammerstingl R; Gruber-Rouh T
    Cancer Biother Radiopharm; 2024 Apr; 39(3):196-202. PubMed ID: 33481646
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response.
    Hu J; Maybody M; Cao G; Wang X; Chen H; Zhu X; Yang R; Wang X
    Cancer Imaging; 2016 Oct; 16(1):32. PubMed ID: 27716376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Wang Z; Chen R; Duran R; Zhao Y; Yenokyan G; Chapiro J; Schernthaner R; Radaelli A; Lin M; Geschwind JF
    Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1548-56. PubMed ID: 26001366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
    Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
    Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early prediction of 1-year tumor response of hepatocellular carcinoma with lipiodol deposition pattern through post-embolization cone-beam computed tomography during conventional transarterial chemoembolization.
    Tsai YC; Shih JH; Hwang HE; Chiu NC; Lee RC; Tseng HS; Liu CA
    Eur Radiol; 2021 Oct; 31(10):7464-7475. PubMed ID: 33765160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of Vascular Lake Phenomenon Before Embolization for the Prediction of Lipiodol Uptake for Intermediate-Stage Hepatocellular Carcinoma Patients that Underwent cTACE.
    Hu B; Zhong BY; Zhang L; Dai C; Li W; Shen J; Huang P; Zhang S; Li Z; Ni CF
    Cardiovasc Intervent Radiol; 2020 Oct; 43(10):1460-1467. PubMed ID: 32500251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial.
    Vogl TJ; Langenbach MC; Hammerstingl R; Albrecht MH; Chatterjee AR; Gruber-Rouh T
    Hepatol Int; 2021 Jun; 15(3):685-694. PubMed ID: 34043158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethiodized oil as an imaging biomarker after conventional transarterial chemoembolization.
    Mendiratta-Lala M; Aslam A; Bai HX; Chapiro J; De Baere T; Miyayama S; Chernyak V; Matsui O; Vilgrain V; Fidelman N
    Eur Radiol; 2024 May; 34(5):3284-3297. PubMed ID: 37930412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.
    Adam LC; Savic LJ; Chapiro J; Letzen B; Lin M; Georgiades C; Hong KK; Nezami N
    Clin Imaging; 2022 Sep; 89():112-119. PubMed ID: 35777239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Lipiodol uptake in angiography and computed tomography for the diagnosis of malignant versus benign hepatocellular nodules in cirrhotic liver.
    Langenbach MC; Vogl TJ; von den Driesch I; Kaltenbach B; Scholtz JE; Hammerstingl RM; Gruber-Rouh T
    Eur Radiol; 2019 Dec; 29(12):6539-6549. PubMed ID: 31236701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of lipiodol deposition after chemoembolization: comparison between cone-beam CT and multidetector CT.
    Chen R; Geschwind JF; Wang Z; Tacher V; Lin M
    J Vasc Interv Radiol; 2013 Dec; 24(12):1837-44. PubMed ID: 24094672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.
    Savic LJ; Chapiro J; Funai E; Bousabarah K; Schobert IT; Isufi E; Geschwind JH; Stark S; He P; Rudek MA; Perez Lozada JC; Ayyagari R; Pollak J; Schlachter T
    Eur Radiol; 2021 May; 31(5):3002-3014. PubMed ID: 33063185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria.
    Shim JH; Han S; Shin YM; Yu E; Park W; Kim KM; Lim YS; Lee HC
    J Vasc Interv Radiol; 2013 Mar; 24(3):316-25. PubMed ID: 23312990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipiodol retention pattern after TACE for HCC is a predictor for local progression in lesions with complete response.
    Dioguardi Burgio M; Sartoris R; Libotean C; Zappa M; Sibert A; Vilgrain V; Ronot M
    Cancer Imaging; 2019 Nov; 19(1):75. PubMed ID: 31730491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angio-Computed Tomograph-Guided Immediate Lipiodol Computed Tomograph for Diagnosis of Small Hepatocellular Carcinoma Lesions during Transarterial Chemoembolization.
    Liu FY; Li X; Yuan HJ; Guan Y; Wang MQ
    Chin Med J (Engl); 2018 Oct; 131(20):2410-2416. PubMed ID: 30334525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing HCC arterial tumour vascularisation on baseline imaging and after lipiodol cTACE: how do estimations of enhancing tumour volumes differ on contrast-enhanced MR and CT?
    Luedemann WM; Geisel D; Gebauer B; Schnapauff D; Chapiro J; Wieners G; Steffen I; Kahn J
    Eur Radiol; 2020 Mar; 30(3):1601-1608. PubMed ID: 31811428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of tumor response on CT with pathologically proven necrosis in hepatocellular carcinoma treated by conventional transcatheter arterial chemoembolization: threshold value of intratumoral Lipiodol accumulation predicting tumor necrosis.
    Park C; Gwon DI; Chu HH; Kim JW; Kim JH; Ko GY
    Abdom Radiol (NY); 2021 Aug; 46(8):3729-3737. PubMed ID: 33141259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of intra-procedural transcatheter intraarterial contrast-enhanced ultrasonography (IA-CEUS) in predicting the short-term efficacy of conventional transarterial chemoembolization (cTACE).
    Fei X; Wang ZJ; Li Y; Han P; Li XH; Jiang B
    Transl Cancer Res; 2020 May; 9(5):3600-3609. PubMed ID: 35117723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.
    van Breugel JMM; Geschwind JF; Mirpour S; Savic LJ; Zhang X; Duran R; Lin M; Miszczuk M; Liapi E; Chapiro J
    Theranostics; 2019; 9(13):3674-3686. PubMed ID: 31281506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical Shift MRI Monitoring of Chemoembolization Delivery for Hepatocellular Carcinoma: Multicenter Feasibility of Initial Clinical Translation.
    Gordon AC; Lewandowski RJ; Li W; Zhong X; Kannengiesser SAR; Miller FH; Salem R; Rilling WS; Larson AC; White SB
    Radiol Imaging Cancer; 2023 May; 5(3):e220019. PubMed ID: 37233207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.